MeSH tree: D02.092.570
A new research paper was published in Aging, titled "Effect of deferoxamine and ferrostatin-1 on salivary gland dysfunction in ovariectomized rats."
Apr 26, 2023
0
63
For high-risk outpatients with COVID-19, treatment with oral fluvoxamine plus budesonide reduces the incidence of severe disease needing advanced care, according to a study published online April 18 in the Annals of Internal ...
Apr 18, 2023
0
33
For patients with mild-to-moderate COVID-19, treatment with fluvoxamine does not improve time to sustained recovery versus placebo, according to a study published online Jan. 12 in Journal of the American Medical Association.
Jan 13, 2023
0
35
A new meta-analysis shows that psychiatric medications can give some protection against COVID-19, with the common antidepressant fluvoxamine showing the strongest effect. Patients taking fluvoxamine showed reduced symptoms, ...
Dec 15, 2022
0
186
A new research paper titled "Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma" has been published in Oncotarget.
Dec 13, 2022
0
44
A study testing drugs that are used for other conditions for their potential in treating COVID-19 has found that the antidepressant fluvoxamine (brand name Luvox) offered no benefit, at least at an initial smaller dose.
Oct 20, 2022
0
45
Two drugs touted as potential COVID-19 treatments, ivermectin and fluvoxamine, don't do a thing to improve patients' oxygen levels and keep them out of the hospital or the morgue, a new clinical trial has shown.
Aug 18, 2022
1
69
In work published in the New England Journal of Medicine, researchers—led by the University of Minnesota Medical School and School of Public Health—have found that metformin, a commonly prescribed diabetes medication lowers ...
Aug 18, 2022
0
1498
In a major new development in the quest to develop better gene therapies with which to treat a host of diseases, researchers at the University of Massachusetts Amherst and UMass Chan Medical School recently announced that ...
Jul 25, 2022
0
181
The antidepressant drug fluvoxamine and the gout drug colchicine are not recommended for patients with mild or moderate COVID-19 because there is currently insufficient evidence that they improve important outcomes for patients, ...
Jul 13, 2022
0
82
